Abstract 1950: Impact of Sirolimus-Eluting Stent and Paclitaxel-Eluting Stent on the Outcome of Patients with Sirolimus-Eluting Stent Failure: Multicenter Registry in Asia
Background and Purpose: Sirolimus-eluting stent failure (restenosis after Sirolimus-eluting stent implantation: SES-F) remains challenging problem and optimal treatment has not been established.
Methods: A total of 308 patients with 359 SES-F lesions (male 71.4%, mean age 70.8%, LMT 7.0%, LAD 45.1%, LCX 26.2%, RCA 17.8%, SVG 3.9%) were treated with SES (mean lesion length 25.9 ± 12.2 mm, mean stent length 30.9 ± 15.5 mm) and Paclitaxel-eluting stent (PES) (mean lesion length 28.8 ± 11.9 mm, mean stent length 33.1 ± 18.9 mm). We evaluate immediate and long-term clinical results by 6 and 12 months angiography.
Results: The baseline clinical characteristics between 2 groups were similar. See table⇓ for clinical results.
Conclusion: The use of SES and PES in patients with restenosis after SES implantation was safe with low complications. Patients treated with SES showed lesser rate of restenosis compared with PES.